MILFORD, Mass., Sept. 20, 2013 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer of life sciences tools, bulk plasma, and quality controls for diagnostic companies and clinical laboratories, announced an expansion of its research and manufacturing facilities at its Milford, Massachusetts headquarters. The addition of the state-of-the-art facility was driven by new companion diagnostic manufacturing opportunities with key diagnostic partners and enhances the company's ability to manufacture innovative molecular diagnostic kits and components used in in vitro diagnostics and companion diagnostics under stringent design control and quality systems.
"The expansion of our research and manufacturing capabilities is an important element in our overall growth strategy for SeraCare," said Charlie Mamrak, CEO of SeraCare. "Over the past year, we have made a number of significant investments including the recent acquisition of KPL, a leader in immunoassay reagents, and implementation of SAP enterprise resource planning software. These investments position SeraCare for continued growth in both our existing customer base as well as emerging markets such as molecular and companion diagnostics."
Under this initiative, SeraCare is adding five thousand square feet of space to its Milford research and manufacturing building. This state-of-the-art facility will include an ISO 8 classified clean room, four advanced molecular laboratories and a sophisticated air handling and purifying system. The new laboratories will also feature polymerase chain reaction (PCR) capabilities, amplicon segregation process design and sequencing instrumentation to aid in the development of molecular diagnostic kits and components.
About SeraCare Life Sciences
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, AccuTrak™, AccuSpan™, AccuSet™ and AccuVert™ panels, KPL™ antibodies and immunoassay reagents, SeraCon™ processed plasma, specialty human blood products, and Complete BioCollections™ materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, and services segments of healthcare.
Marsha Ann Marsh
SeraCare Life Sciences
+1 508.244.6400 ext. 6106
|SOURCE SeraCare Life Sciences|
Copyright©2012 PR Newswire.
All rights reserved